title: Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results.
abstract: Strategies to delay progression of established renal disease have primarily been directed at examining the class of antihypertensive therapy and/or the level of blood pressure control. In diabetic renal disease many trials have noted a protective role of ACE inhibitor-based therapy over non-ACE inhibitor-based therapy. This paper reviews recent clinical trials evaluating hypertension-related kidney disease including the interim results of the African-American Study of Kidney Diseases and Hypertension (AASK) Study, to date the largest prospective study of African-American patients with kidney disease due to hypertension. This trial reports a renoprotective effect of ACE inhibitor-based therapy over calcium-channel antagonist- based therapy. The renoprotective effect of ACE inhibitor-based therapy may, in part, be due to their antiproteinuric effect independent of blood pressure lowering.
authors.affiliation: Emory University School of Medicine, Atlanta, GA, USA. jlea@emory.edu
authors.forename: Janice P
authors.initials: JP
authors.lastname: Lea
authors.forename: Denyse T
authors.initials: DT
authors.lastname: Brown
authors.forename: Michael
authors.initials: M
authors.lastname: Lipkowitz
authors.forename: John
authors.initials: J
authors.lastname: Middleton
authors.forename: Keith
authors.initials: K
authors.lastname: Norris
mesh_terms: D001741:Black or African American; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003928:Diabetic Nephropathies / Q000517:prevention & control; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications*; D007674:Kidney Diseases / Q000517:prevention & control*; D011507:Proteinuria / Q000517:prevention & control
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors